Literature DB >> 19084480

Hepatitis C in the elderly: epidemiology, natural history, and treatment.

Ayse L Mindikoglu1, Ram R Miller.   

Abstract

Hepatitis C continues to be a major public health problem affecting approximately 3% of the global population. According to the World Health Organization, an estimated 170 million people have chronic hepatitis C. Ten percent to 20% of those who are chronically infected with hepatitis C will progress to cirrhosis and 5% will develop hepatocellular carcinoma. Although the safety and efficacy of hepatitis C therapies have been studied extensively in patients between the ages of 18 and 65, patients who are older than 65 still remain an understudied and difficult-to-treat population. This review discusses the epidemiology, natural history, and treatment of chronic hepatitis C in older adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084480      PMCID: PMC2950699          DOI: 10.1016/j.cgh.2008.07.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  34 in total

1.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Interferon therapy for patients more than 60 years of age with chronic hepatitis C.

Authors:  N Horiike; T Masumoto; K Nakanishi; K Michitaka; K Kurose; I Ohkura; M Onji
Journal:  J Gastroenterol Hepatol       Date:  1995 May-Jun       Impact factor: 4.029

3.  Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea Study.

Authors:  F Monica; F Lirussi; G Nassuato; M R Castelletto; A Mottola; L Okolicsanyi
Journal:  J Viral Hepat       Date:  1998-09       Impact factor: 3.728

4.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Authors:  Nezam H Afdhal; Douglas T Dieterich; Paul J Pockros; Eugene R Schiff; Mitchell L Shiffman; Mark S Sulkowski; Teresa Wright; Zobair Younossi; Betty L Goon; K Linda Tang; Peter J Bowers
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

5.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  Treatment of hepatitis C virus in elderly persons with interferon alpha.

Authors:  D H Van Thiel; L Friedlander; P Caraceni; P J Molloy; R J Kania
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-11       Impact factor: 6.053

7.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Hepatitis C virus infection in the elderly.

Authors:  A M Brind; J P Watson; O F James; M F Bassendine
Journal:  QJM       Date:  1996-04

10.  Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C.

Authors:  Nunziata Alessi; Maria Antonietta Freni; Aldo Spadaro; Antonino Ajello; Santi Turiano; Domenico Migliorato; Oscar Ferraù
Journal:  Infez Med       Date:  2003-12
View more
  7 in total

1.  Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis.

Authors:  Kimberly J Alvarez; Arlene Smaldone; Elaine L Larson
Journal:  Curr Infect Dis Rep       Date:  2016-03       Impact factor: 3.725

Review 2.  Liver physiology and liver diseases in the elderly.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  Influential Factors of Successful Hepatitis C Treatment in Elderly Patients.

Authors:  Jennifer Andres; Mandee Noval; Christine Mauriello; Derek Peiffer; Huaqing Zhao
Journal:  Innov Pharm       Date:  2019-09-19

4.  Hepatitis C virus and lichen planus: the real association.

Authors:  Nima Mahboobi; Farzaneh Agha-Hosseini; Kamran Bagheri Lankarani
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

5.  Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.

Authors:  Chih-Wei Tseng; Ting-Tsung Chang; Shinn-Jia Tzeng; Yu-Hsi Hsieh; Tsung-Hsing Hung; Hsiang-Ting Huang; Shu-Fen Wu; Kuo-Chih Tseng
Journal:  Clin Interv Aging       Date:  2016-03-17       Impact factor: 4.458

6.  Safety and efficacy of directly-acting antiviral therapy for chronic hepatitis C virus in elderly people.

Authors:  Adriano De Santis; Daniela Maggi; Federica Lubrano Lobianco
Journal:  Aging Med (Milton)       Date:  2021-12-21

7.  High prevalence of occult hepatitis C infection in predialysis patients.

Authors:  Luís Henrique Bezerra Cavalcanti Sette; Edmundo Pessoa de Almeida Lopes; Nathália Campello Guedes Dos Anjos; Lucila Maria Valente; Sávio Augusto Vieira de Oliveira; Norma Lucena-Silva
Journal:  World J Hepatol       Date:  2019-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.